Month: October 2026

New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families

STOUGHTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, and Boston Legacy FC, Boston’s professional women’s soccer club, today announced an expanded, multi-year partnership to deepen their commitment to Boston communities and create more opportunities for neurodivergent children and families, including those living with attention-deficit/hyperactivity disorder (ADHD).

Building on their existing Collegium Sensory Room partnership, Collegium and Boston Legacy FC will help youth soccer coaches better support neurodivergent children and bring families, experts and community leaders together through an annual Collegium Summit: Sports for All. The expanded partnership extends their work beyond matchday into communities across Massachusetts and deepens Collegium’s local commitment ahead of its headquarters move to Boston in early 2027.

ADHD is common among school-age children. The Centers for Disease Control and Prevention (CDC) reports, based on 2022 National Survey of Children’s Health data, that 10.5% of U.S. children aged 3–17, or 6.5 million children, have ever received an ADHD diagnosis.¹ Published research indicates that children with ADHD may participate in youth sports less often and less successfully, and that youth sport coaches have reported less positive attitudes about including these children on their teams.² The partnership’s new programs will help coaches better support children with ADHD and bring families and experts together to explore ways to make sports more accessible and inclusive.

“As a leader in ADHD, Collegium recognizes the importance of addressing every part of life that matters to those living with ADHD and their families, from the classroom to the soccer pitch to the dinner table,” said Vikram Karnani, President and Chief Executive Officer, Collegium Pharmaceutical. “We believe healthier people and stronger communities go hand in hand. Our partnership with Boston Legacy FC puts that belief into action by helping children participate in sports, build friendships and feel included, and by giving coaches practical training to support them. Massachusetts is where we begin, and we will keep growing this effort for families everywhere.”

The expanded partnership includes:

• Soccer Coaching Certification Initiative: Boston Legacy FC and Collegium will launch a coaching certification initiative to equip coaches to better support kids with ADHD and other neurodevelopmental conditions. Coaches will have the opportunity to earn a certification recognizing their completion of the training. The initiative is planned to launch in Massachusetts in 2027 and continue through 2029, with regional and national expansion envisioned.
• Annual Collegium Summit: Sports for All: Boston Legacy FC will host an annual Collegium Sports for All Summit at its new Performance Center in Brockton, Mass., bringing together patients, caregivers, medical professionals, advocates, athletes and community leaders to discuss accessibility, neurodiversity and participation in sports. The gathering will provide a forum to share experiences and explore ways to better support neurodivergent children and families.
• Continued Sensory Inclusion: The partnership will continue to support the Collegium Sensory Room, which provides a quieter space for fans who need a break from the noise, crowds and visual stimulation of matchday.

The partnership also includes an increased presence for Collegium as an Official Partner of Boston Legacy FC. Collegium’s logo will appear on the upper back of all Boston Legacy FC game kits, including the primary, secondary and goalkeeper kits, at every home and away match. Collegium will also have permanent signage on the press box at White Stadium, joining the club’s other long-term partners.

“We’re proud to expand our partnership with Collegium and build on our shared commitment to making soccer more inclusive and accessible. From featuring Collegium on our kits to expanding our community initiatives, this partnership allows us to extend our impact beyond the pitch and create meaningful opportunities for children and families to feel welcomed, supported and connected through sport,” said Amina Bulman, Chief Revenue Officer of Boston Legacy FC. “We’re excited about what we can achieve together and the meaningful, lasting impact we can make in our communities.”

The expanded partnership builds on community programming already underway. On Oct. 24, 2026, Collegium presented an adaptive soccer clinic in collaboration with Boston Legacy FC, UMass Shriver Center, and Mass Youth Soccer. The clinic, held at SBLI Fields at Progin Park, paired children with volunteer buddies for a supportive soccer experience, providing an early example of the inclusive community programming.

ABOUT COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system (CNS) and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

With a portfolio of differentiated ADHD medications and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.

For more information, please visit collegiumpharma.com or find us on LinkedIn.

ABOUT BOSTON LEGACY FC

Boston Legacy FC is the 15^th team in the National Women’s Soccer League (NWSL), currently playing its inaugural season at Gillette Stadium and Centreville Bank Stadium. Founded and led by women, the club is committed to creating a home for the greatest female athletes of our time, building upon the supercharged legacy of Boston’s historic sports teams, cultivating a community of fans with impact at its core, and forging new connections across our city through sport. For more information, please visit bostonlegacyfc.com or its social media platforms – LinkedIn, Instagram, Twitter (X), Tiktok, Bluesky, Facebook

MEDIA CONTACTS

Boston Legacy FC Media Contact
Sara Rooke
Director of Communications, Boston Legacy FC
srooke@bostonlegacyfc.com
617-872-9453

Collegium Media Contact
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com

REFERENCES

1. Danielson ML, et al. ADHD Prevalence Among U.S. Children and Adolescents in 2022. Journal of Clinical Child & Adolescent Psychology, 2024;53(3):343–360. https://stacks.cdc.gov/view/cdc/160350

2. O’Connor BC, Fabiano GA, et al. Effects of a Summer Treatment Program on Functional Sports Outcomes in Young Children with ADHD. PubMed Central. Cites Beyer et al., 2008, International Journal of Sports Science & Coaching, 3, 555–563, for coach attitudes. https://pmc.ncbi.nlm.nih.gov/articles/PMC4399495

Photos accompanying this announcement are available at: 
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a410b80-fea3-4a0b-9b4a-89ea849a75d7
https://www.globenewswire.com/NewsRoom/AttachmentNg/518a5af8-5b64-40e0-af62-774efda33cdf
https://www.globenewswire.com/NewsRoom/AttachmentNg/36916660-abce-4652-9943-64a9f9d07338
https://www.globenewswire.com/NewsRoom/AttachmentNg/81302822-75e7-474b-84bd-782639b75130
https://www.globenewswire.com/NewsRoom/AttachmentNg/0ff18e8f-8874-49cf-a0ae-0d4f99c9ed25

Seven-Figure Annual Minimum Commitment Builds on a Relationship that Started with an Image of the International Space Station in 2020 and Has Grown More than 40-Fold

HEO used Satellogic’s NewSat 46, from a distance of 17.22 km with an image resolution of 3 cm/px, to capture this image of AST’s BlueWalker 3 satellite on October 24, 2026.

ORLANDO, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) — Satellogic Inc. (NASDAQ: SATL), the infrastructure company for Persistent Global Intelligence (PGI), and HEO, a space intelligence company that images and analyzes objects in orbit on demand, today announced a three-year agreement under which Satellogic will provide HEO access to its high-resolution constellation to conduct Non-Earth Imaging (NEI) and generate insights, supporting space domain awareness globally. The recently signed agreement runs through 2029 and includes a seven-figure minimum annual commitment for each of its three years.

The agreement, announced today at Economist Enterprise’s Space Economy Summit, extends a collaboration that dates back to September 2020, when HEO approached Satellogic about imaging objects in orbit. The companies began with a small, co-funded engineering effort to adapt Satellogic’s Earth observation satellites for non-Earth imaging, and the first capture was the International Space Station. Satellogic is HEO’s longest-standing Earth observation constellation partner. Successful captures using Satellogic’s fleet have grown from about 30 in 2021, the first full year of service, to over 1,600 under the most recent agreement in the last year.

“HEO came to us in 2020 with a question few people in our industry had asked yet: what can an Earth observation satellite see if you point it at what’s in orbit?” said Emiliano Kargieman, CEO and Co-Founder of Satellogic. “Our first project was a picture of the International Space Station. Six years and well over a thousand captures per year later, HEO has taken the capability and become a leader in NEI and space domain awareness.”

HEO has access to more satellites through Satellogic than through any other provider in its network. That means more revisit opportunities for each target, more viewing angles, and faster time to first image. The agreement covers Satellogic’s NewSat Mark IV, Mark V and Mark VI satellites, including its newest inter-satellite link (ISL)-equipped spacecraft.

“Satellogic was one of our earliest partners to back non-Earth imaging, and our partnership has continued to grow through collaboration and innovation ever since,” said Dr. Will Crowe, CEO and Co-Founder of HEO. “Together, we’ve continued to find new ways to adapt their fleet for satellite inspection, improving the quality of imagery and insights available to our customers. Their satellites and our shared innovation give us flexibility as we work to view more objects in space and deliver better data to the government and defense customers whose missions depend on it. The three-year commitment gives us the confidence to keep pushing what’s possible.”

About Satellogic

Founded in 2010, Satellogic (NASDAQ: SATL) builds the infrastructure for Persistent Global Intelligence (PGI): continuous, proactive awareness of the places, assets, and activities that matter. The company combines high-cadence satellite collection, best-in-class technology, AI-accelerated workflows, and sovereign-trusted architecture to help customers move from episodic imagery to persistent monitoring programs.

Satellogic serves allied defense and intelligence agencies, civil governments, and commercial markets that need reliable, scalable awareness of change across large portfolios of sites. Customers can begin with discovery, expand into persistent monitoring, and build toward dedicated or sovereign-controlled capacity as their mission requirements grow. To learn more, please visit: https://www.satellogic.com.

About HEO

HEO is building the intelligence layer for space. We image objects in orbit on demand, turning existing satellites into inspection platforms and building our own sensors where coverage gaps remain. Our software automates tasking, capture and analysis, turning imagery into decision-ready intelligence about satellites, debris and other objects in orbit. HEO operates internationally, with offices in Australia, France, Japan, the United Kingdom and the United States. Our goal is to make any image in the Solar System available on Demand. To learn more, please visit: https://www.heospace.com/

About the Economist Enterprise’s 4th annual Space Economy Summit

Economist Enterprise’s 4th annual Space Economy Summit, taking place October 28–29, 2026, at the University of Central Florida in Orlando, convenes senior leaders from government, space, investment and industry. Under the theme “Maximising returns to Earth: the infinite potential of space,” the summit examines how innovation in orbit can deliver measurable commercial and strategic value across the wider economy.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on Satellogic’s current expectations and beliefs concerning, among other things, the capabilities, performance, and potential applications of Satellogic’s satellites, constellations, satellite software, and pipeline. Although we believe our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot give any assurance that we either will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions, including risks related to the performance of satellites and software once in orbit and reliance on third parties. Many actual events and circumstances are beyond the control of the Company. Many factors could cause actual future results to differ materially from the forward-looking statements in this press release, including but not limited to the risks and uncertainties described in the “Risk Factors” section of Satellogic’s Annual Report on Form 10-K and other documents filed or to be filed by Satellogic from time to time with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Satellogic assumes no obligation and does not intend to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

Satellogic Investor Relations:
ir@satellogic.com

Satellogic Media Relations:
pr@satellogic.com

HEO:
media@heospace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c4989eb2-cee3-45fa-90fb-9759da74aa81

Company to report third quarter 2026 financial results on November 5

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the Company’s senior management team will participate in a virtual fireside chat on Friday, November 6, 2026, at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the third quarter ended September 30, 2026, after the market close on Thursday, November 5, 2026.

The live fireside chat can be accessed by clicking here or on the Company’s website at www.vaxart.com.

Investors may submit written questions in advance of the conference call to ir@vaxart.com or through the webcast portal.

A replay of the fireside chat webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com

• Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals
• Poster presentations to include patient perspective about life after lonvo-z treatment
• Intellia to host investor webcast on Thursday, November 12 at 10 a.m. ET

CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16 in Phoenix, Arizona. Intellia also announced that it will host an investor webcast on Thursday, November 12, at 8 a.m. MT / 10 a.m. ET to share highlights from the presentations, provide perspectives from HAE key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

Oral Presentation Details:

• Title: Four-Year Durability/Safety of Lonvoguran Ziclumeran (Lonvo-z) 50 mg in Patients with Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:43 – 4:53 p.m. MT
  Presenter: Danny Cohn, M.D., Ph.D., Associate Professor, Amsterdam University Medical Center, Department of Vascular Medicine, University of Amsterdam; Phase 1/2 and HAELO principal investigator
• Title: Attack-Free and Long-Term Prophylaxis-Free Status Following Treatment with Lonvoguran Ziclumeran in Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:53 – 5:03 p.m. MT
  Presenter: Emel Aygören-Pürsün, M.D., Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University; Phase 1/2 and HAELO principal investigator

Poster Presentation Details:

• Title: Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:05 – 3:20 p.m. MT
  Presenter: Marc Riedl, M.D., Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center, University of California San Diego; HAELO principal investigator
• Title: Lived Experiences of Patients Treated with Lonvoguran Ziclumeran, a One-Time CRISPR Treatment for Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:20 – 3:35 p.m. MT
  Presenter: Padmalal Gurugama, MBBS, M.S., M.D., MRCP, FRCPath, Consultant, Clinical Immunology and Allergy, Cambridge University Hospitals NHS Foundation Trust; Phase 1/2 and HAELO principal investigator
• Title: Long-Term Prophylaxis for Hereditary Angioedema: Treatment Use, Patterns, and Gaps in a U.S. Claims Database
  Poster Session: Monitor 18
  Date and Time: Friday, November 13, 2026, from 4:05 – 4:20 p.m. MT
  Presenter: Raffi Tachdjian, M.D., M.P.H., Associate Clinical Professor of Medicine and Pediatrics, Division of Allergy and Clinical Immunology, David Geffen School of Medicine, University of Los Angeles; HAELO principal investigator
• Title: A One-Time Treatment of Lonvoguran Ziclumeran Improves Quality of Life in Patients with Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 4:35 – 4:50 p.m. MT
  Presenter: William Lumry, M.D., Clinical Professor of Internal Medicine, Allergy and Immunology Division, University of Texas Southwestern Medical School, Medical Director, AARA Research Center; HAELO principal investigator
• Title: Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy, Safety, and Tolerability
  Poster Session: Monitor 16
  Date and Time: Friday, November 13, 2026, from 5:35 – 5:50 p.m. MT
  Presenter: Aleena Banerji, M.D., Professor at Harvard Medical School, Director of Clinical Care, Center for Drug and Vaccine Allergy at Massachusetts General Hospital; HAELO principal investigator

The presentations will be made available on the Scientific Publications & Presentations page of www.intelliatx.com at the start of each respective session.

Intellia Therapeutics Investor Webcast
Intellia will host a live webcast on Thursday, November 12, 2026, at 8 a.m. MT / 10 a.m. ET to review data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE. To join the webcast, visit the Events page of the Investors & Media section of the company’s website at www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days following the call.

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designations by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. In September 2026, the FDA accepted the Biologics License Application (BLA) for lonvo-z and granted Priority Review with a PDUFA target action date of March 10, 2027.

About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran (“lonvo-z”) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of its biologics license application (“BLA”) for lonvo-z, such as the timing of such review and approval based on the Prescription Drug User Fee Act (“PDUFA”) target action date of March 10, 2027 for the BLA; its belief that lonvo-z could permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting; and its expectations regarding its preparations for and the potential success of the commercial launch of lonvo-z, if approved.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the review and approval of the BLA for lonvo-z and the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its recent quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

FORT WAYNE, Ind., Oct. 29, 2026 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. (NASDAQ: FELE), a global leader in the manufacturing and distribution of systems, focused on the movement and management of water, fuel and electricity, today announced that CEO Joe Ruzynski and CFO Jennifer Wolfenbarger will participate along with Investor Relations at the following upcoming investor conferences:

• Northcoast Research Fall Management Forum, November 9^th, virtually
• Baird 2026 Global Industrial Conference, November 10^th, Chicago
• Oppenheimer Winter Industrial Summit, December 8^th, virtually

About Franklin Electric
Franklin Electric is a global leader in the production and marketing of systems and components for the movement of water and energy. Recognized as a technical leader in its products and services, Franklin Electric serves customers worldwide in residential, commercial, agricultural, industrial, municipal and fueling applications. Franklin Electric is proud to be recognized in Newsweek’s lists of America’s Most Responsible Companies 2025, Most Trustworthy Companies 2025, and Greenest Companies 2025. 

Franklin Electric uses our Investor Relations website, Investor Relations | Franklin Electric, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including those relating to market conditions or the Company’s financial results, costs, expenses or expense reductions, profit margins, inventory levels, foreign currency translation rates, liquidity expectations, business goals and sales growth, involve risks and uncertainties, including but not limited to, risks and uncertainties with respect to general economic and currency conditions, various conditions specific to the Company’s business and industry, weather conditions, new housing starts, market demand, competitive factors, changes in distribution channels, supply constraints, effect of price increases,  raw material costs, technology factors, integration of acquisitions, litigation, government and regulatory actions, the Company’s accounting policies, future trends, epidemics and pandemics, and other risks which are detailed in the Company’s Securities and Exchange Commission filings, included in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2025, Exhibit 99.1 attached thereto and in Item 1A of Part II of the Company’s Quarterly Reports on Form 10-Q. These risks and uncertainties may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements made herein are based on information currently available, and the Company assumes no obligation to update any forward-looking statements.

CONTACT:	Jennifer Wolfenbarger / Dean Cantrell
	Franklin Electric Co., Inc.
	260.824.2900

SKNY-1’s Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide’s Initial Food-Intake Suppression and Significant Post-Treatment Increase

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapeutics, today announced initial positive proof-of-concept results from an exploratory pilot study evaluating SKNY-1, its investigational oral drug candidate for obesity and metabolic disorders.

Conducted in an established diet-induced obesity (DIO) mouse model, the study demonstrated statistically significant reductions in body weight and fat mass following oral administration of SKNY-1 compared with vehicle-treated controls.

Importantly, weight reduction occurred without a statistically significant decrease in food consumption, raising the possibility that SKNY-1 may influence metabolic pathways beyond appetite suppression.

The study also identified three potentially meaningful areas of differentiation from the semaglutide reference group: effects on food intake, lean-mass outcomes, and weight regain following treatment discontinuation. Together, these findings expand upon previous SKNY-1 research and support its continued development as a potentially differentiated oral approach to weight management.

“Obesity represents one of the largest and fastest-growing opportunities in healthcare, with the potential for multiple multibillion-dollar therapies,” said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals. “We believe the future of obesity treatment will extend beyond a single class of drugs. Patients have different needs, and there is tremendous opportunity for innovative therapies that work through distinct mechanisms and offer favorable profiles for long-term weight management. What makes SKNY-1 particularly exciting is that our findings point toward a potentially differentiated metabolic approach, with encouraging signals regarding body composition and weight maintenance following treatment discontinuation. We believe these characteristics could become important advantages as we continue advancing SKNY-1, positioning it as a potentially valuable asset within our pipeline and an opportunity to participate in this significant global market.”

Key Findings From the SKNY-1 Pilot Study

Statistically Significant Weight and Fat Reduction

Oral SKNY-1 demonstrated statistically significant reductions in body weight and fat mass compared with vehicle-treated controls. The majority of the treatment-associated weight difference was attributable to fat reduction, providing encouraging evidence of SKNY-1’s activity in an established obesity model.

Favorable Lean-Mass Findings Compared With the Semaglutide Reference Group

At the Day 14 body-composition assessment, oral SKNY-1-treated mice did not demonstrate statistically significant lean-mass loss relative to vehicle controls.

In contrast, semaglutide-treated mice demonstrated statistically significant lean-mass loss compared with vehicle-treated controls.

Limited Weight Regain Following Treatment Discontinuation Compared With Semaglutide

During the two-week observation period following treatment cessation, oral SKNY-1-treated mice demonstrated slow and limited weight regain.

In contrast, semaglutide-treated mice experienced rapid and substantial weight rebound, which was accompanied by a statistically significant increase in food consumption relative to vehicle controls, while oral SKNY-1-treated groups showed no statistically significant increase in food consumption.

Investigating a Potentially Differentiated Metabolic Mechanism
The study’s findings raise the possibility that SKNY-1 may influence energy expenditure, energy utilization, or other metabolic pathways involved in weight regulation, rather than relying primarily on appetite suppression.

These observations provide a scientific rationale for investigating SKNY-1’s potentially differentiated metabolic mechanism.

“One of the most intriguing findings from this pilot study is that SKNY-1 produced significant weight reduction without a statistically significant decrease in food consumption,” said Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals. “The contrasting observations in lean-mass outcomes and weight regain following treatment discontinuation compared with the semaglutide reference group are also scientifically interesting. Together, these findings raise the possibility that SKNY-1 may influence how the body utilizes energy, potentially offering a differentiated metabolic approach to weight management. These results further expand and confirm previous studies, which have demonstrated increased energy expenditure without changes in food intake.”

“Our next study will investigate this hypothesis more directly through measurements of energy expenditure and other metabolic parameters, while further characterizing SKNY-1’s effects on body composition and weight regulation.”

Continued Development of SKNY-1
MIRA is advancing SKNY-1 through longer-term preclinical studies to further assess weight reduction, body composition and metabolic effects, while continuing its IND-enabling development activities and chemistry, manufacturing and controls (CMC) manufacturing efforts to support future clinical development.

About SKNY-1
SKNY-1 is MIRA Pharmaceuticals’ investigational oral drug candidate being developed for obesity and metabolic disorders. The compound is a cannabinoid analog being investigated for its potential effects on biological pathways involved in metabolic regulation.

Previously published preclinical research in a zebrafish model of obesity demonstrated approximately 30% weight reduction, accompanied by maintenance of whole-body density, reductions in hepatic triglyceride accumulation, and changes in appetite-related signaling.

The latest pilot study in diet-induced obese mice expands this exploratory research into a mammalian obesity model, providing additional evidence of SKNY-1’s potential as an oral therapeutic candidate for obesity.

About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics. The Company’s pipeline includes Ketamir-2 for chemotherapy-induced peripheral neuropathy (CIPN), which has completed Phase 1 and is advancing toward Phase 2a under an active IND; MIRA-55, an investigational oral drug candidate for inflammatory pain; and SKNY-1, an investigational oral drug candidate for obesity. Following scientific review, the U.S. Drug Enforcement Administration has determined that Ketamir-2, MIRA-55, and SKNY-1 are not classified as controlled substances.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at http://www.mirapharmaceuticals.com/. Forward-looking statements should be considered in light of these risks and uncertainties.

Investor and Media Contact
Krystina Quintana
MIRA Pharmaceuticals
info@mirapharma.com 
(786) 432-9792

SUNNYVALE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — GSI Technology, Inc. (Nasdaq: GSIT), the inventor of the Associative Processing Unit (APU), a paradigm shift in artificial intelligence (AI) and high-performance compute processing, providing true compute-in-memory technology, today announced that management will attend the 15^th Annual ROTH Technology Conference on Wednesday, November 18, 2026, at the Hard Rock Hotel in New York, NY. On behalf of the company, Didier Lasserre, Vice President of Sales and Investor Relations, will host one-on-one meetings.

For conference details or to schedule a one-on-one meeting, please contact your ROTH representative. To learn more and submit a registration request, visit www.roth.com/tech2026. GSI Technology’s slide presentation will be available on the company’s website under the Events and Presentations tab: https://ir.gsitechnology.com/events-and-presentations.

ABOUT GSI TECHNOLOGY
GSI Technology is at the forefront of the AI revolution with our groundbreaking APU technology, designed for unparalleled efficiency in billion-item database searches and high-performance computing. GSI’s innovations, Gemini-I® and Gemini-II®, offer scalable, low-power, high-capacity computing solutions that redefine edge computing capabilities. GSI Technology is headquartered in Sunnyvale, California, and has sales offices in the Americas, Europe, and Asia. For more information, please visit www.gsitechnology.com.

Source: GSI Technology, Inc.

Contacts:
Investor Relations
Hayden IR
Kim Rogers
541-904-5075
Kim@HaydenIR.com

Media Relations
Finn Partners for GSI Technology
Ricca Silverio
(415) 348-2724
gsi@finnpartners.com

Company
GSI Technology, Inc.
Douglas M. Schirle
Chief Financial Officer
408-331-9802

• U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis
• Company expands pipeline through research collaboration of a novel, oral macrocyclic peptide-based neonatal Fc receptor antagonist program from Generian Pharmaceuticals
• Sheila Gujrathi, M.D., appointed Executive Chair of Processa’s Board of Directors
• Cash runway expected to fund operations into the second half of 2029

VERO BEACH, FL, Oct. 29, 2026 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced continued execution following its acquisition of Vidya Therapeutics (“Vidya”). Progress includes U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) application for a Phase 2 study of VT-7208 in chronic spontaneous urticaria (CSU), expansion of the pipeline through a research collaboration with Generian Pharmaceuticals, and the appointment of Sheila Gujrathi, M.D., as Executive Chair of the Board of Directors.

Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase 2 proof-of-concept programs, including CSU, food allergy and relapsing multiple sclerosis. These programs provide multiple opportunities to evaluate VT-7208 across distinct immune-mediated diseases. The acquisition was accompanied by an approximately $200 million private placement from leading institutional healthcare investors. The Company expects its current cash resources to support operations into the second half of 2029.

“Since the Vidya transaction, we have made great progress in executing our strategy,” said Dr. Gujrathi. “The FDA clearance of the CSU IND is an exciting step toward advancing VT-7208 across three planned Phase 2 programs. At the same time, the Generian collaboration expands our pipeline around another high-value, clinically validated immune target. With funding in place to support these programs, our focus is on disciplined execution and generating the data needed to demonstrate the potential of the portfolio.”

“Sheila has been an invaluable partner to the Board since the Vidya transaction, and her experience building biotechnology companies, advancing clinical programs and creating long-term value makes her well suited to lead the Board through this next phase,” said Justin Yorke, former Chair of the Processa Board of Directors. “We are pleased to have her step into the Executive Chair role as Processa advances its clinical strategy and broader pipeline.”

FDA Clears IND for Phase 2 Study of VT-7208 in CSU

The FDA has cleared the IND application for VT-7208 in CSU, enabling Processa to advance the program into a Phase 2 study in adults with moderate-to-severe disease.

The planned multicenter, randomized, double-blind, placebo-controlled study is expected to enroll approximately 120 adults whose disease is not adequately controlled with H1 antihistamines. The study will evaluate VT-7208 versus placebo over 12 weeks and assess efficacy, safety, tolerability and pharmacologic activity.

CSU is a chronic inflammatory disease characterized by recurrent hives, swelling or both without an identifiable external trigger and affects an estimated 1.6 to 2 million U.S. adults. Despite available therapies, a meaningful proportion of patients remain inadequately controlled, underscoring the need for additional treatment options.

Pipeline Expansion Through Research Collaboration

Processa also announced that it has entered into a research collaboration and exclusive option agreement with Generian Pharmaceuticals, a UPMC Enterprises portfolio company that emerged from the UPMC/University of Pittsburgh ecosystem for breakthrough science, to advance a novel oral macrocyclic peptide-based neonatal Fc receptor (FcRn) antagonist program, further expanding Processa’s immunology pipeline.

The collaboration targets a clinically validated mechanism for treating IgG-mediated autoimmune diseases and supports the companies’ shared strategy of developing differentiated oral therapeutic alternatives to currently available injectable FcRn therapies. The program complements VT-7208 and reflects Processa’s broader strategy to selectively expand its pipeline around clinically validated immune targets, using capital-efficient structures that provide access to novel programs while preserving flexibility as the science matures.

Sheila Gujrathi Appointed Executive Chair

Dr. Gujrathi has been appointed Executive Chair of the Processa Board of Directors. She has served on the Board since Processa’s acquisition of Vidya in June 2026, where she was founder and its executive chair. In this expanded role, she will support the management team on corporate strategy, capital allocation and organizational development.

Dr. Gujrathi is a physician-scientist, biotechnology entrepreneur and drug developer with extensive experience building biotechnology companies and advancing therapies in immunology. Her prior leadership roles include Executive Chair of Ventyx Biosciences, Chair of Turning Point Therapeutics, Chair of ADARx Pharmaceuticals, co-founder and Chief Executive Officer of Gossamer Bio, and Chief Medical Officer of Receptos.

ABOUT PROCESSA PHARMACEUTICALS

Processa Pharmaceuticals is a clinical-stage pharmaceutical company advancing innovative drug candidates through a disciplined, science-driven development strategy. Following the acquisition of Vidya Therapeutics, Processa’s lead program is VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. VT-7208 is a potentially best-in-class BTK inhibitor (BTKi) designed to improve on the efficacy and safety of early-generation programs. Processa is developing VT-7208 in three parallel programs: food allergy and chronic spontaneous urticaria (CSU) in immunology, and relapsing multiple sclerosis (RMS) in neurology, where its CNS-penetrant profile addresses an area of high unmet need. With Phase 1 complete, the company intends to advance all three programs toward Phase 2 proof-of-concept studies.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Processa, Vidya, the concurrent private placement financing and the acquisition of Vidya by Processa (the “Transactions”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Transactions and the expected effects, perceived benefits or opportunities and related timing with respect to the Transactions; expectations regarding or plans for VT-7208, including its planned clinical trials, research and development programs and the expected timing for key milestones; the potential benefits of VT-7208 and other clinical and preclinical programs; the perceived benefits of the research collaboration and exclusive option agreement with Generian Pharmaceuticals; and expectations regarding the use of proceeds from the concurrent private placement financing and cash runway expectations therefrom, including such proceeds funding the company into the second half of 2029. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the company or the Transactions will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those uncertainties and factors described under the heading “Risk Factors” and in the company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on October 5, 2026 , as well as discussions of potential risks, uncertainties, and other important factors included in other filings by the company from time to time, as well as risk factors associated with companies, such as Processa, that operate in the biotechnology industry. Should one or more of these risks or uncertainties materialize, or should any of the company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The company does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in the company.

CONTACTS
Investors
Priyanka Shah
Elephant Head Communications
pshah@elephantheadcommunicationsllc.com

Media
Ryan Flinn
The Grace Group
ryan@gracegroup.us

Drilling continues at D Zone as GoldHaven explores a silver-rich mineralized system sharing key geological characteristics with Coeur Mining’s Silvertip deposit

VANCOUVER, British Columbia, Oct. 29, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company”) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) is pleased to announce that its inaugural 2026 diamond drilling program at its flagship Magno Project in northwestern British Columbia has reached approximately 3,000 metres, with exploration advancing across its high-grade silver-lead-zinc and tungsten targets.

Recent drilling at D Zone has encountered multiple intervals of semi-massive to massive sulphide mineralization, further advancing GoldHaven’s exploration of a silver-lead-zinc system sharing key geological characteristics with Coeur Mining’s Silvertip deposit. Drilling continues across additional targets, with laboratory assays pending.

Highlights

• Over 3,000 metres drilled: GoldHaven reaches a significant milestone in its inaugural 2026 drilling program at Magno, targeting both silver-lead-zinc and tungsten mineralization.
• High-grade historical silver: Previous D Zone drilling reported 7.6 metres grading 240 g/t silver, 4.73% lead and 4.74% zinc.
• High-grade silver surface samples: GoldHaven’s 2025 exploration program returned up to 2,370 g/t silver at Magno and 1,390 g/t silver at Middle D.
• Silvertip geological comparison: Magno exhibits carbonate replacement-style mineralization, including manto and chimney-style features also characteristic of Coeur Mining’s Silvertip deposit.
• Additional massive sulphides intersected: Drill hole GOH26-15 encountered approximately 18.5 metres of massive sulphide and 9 metres of semi-massive sulphide mineralization, with assays pending.

Advancing Silver-Lead-Zinc Exploration at D Zone

Further to the Company’s October 22nd news release, which described four of the first five completed drill holes at Middle D intersecting semi-massive to massive sulphide mineralization, the latest diamond drill hole in this area (GOH26-15) has intersected approximately 18.5 m and 9 m of massive sulphide and semi-massive sulphide mineralization, respectively. This is in addition to the previously announced GOH26-10 and GOH26-13 which encountered cumulative visually identified mineralized intervals of approximately 10.75 metres and 13 metres, respectively, across separate intervals. True widths are unknown.

The mineralization includes visible galena and sphalerite, with drilling continuing to evaluate the geometry and potential continuity of the system. Laboratory assays remain pending.

CEO Commentary:

“Reaching 3,000 metres in our inaugural drill program is an important milestone, but we’re particularly encouraged by the silver-lead-zinc potential emerging at D Zone,” commented Rob Birmingham, President and CEO of GoldHaven.

“Magno shares compelling geological characteristics with Coeur Mining’s Silvertip deposit. With multiple sulphide intersections and assays approaching, we’re excited to further evaluate the potential of this system.”

Figure 1: Ongoing drilling at D Zone, Magno Project, near Highway 37, British Columbia.

GoldHaven’s Magno Project Shares Key Geological Characteristics with Coeur Mining’s Silvertip Deposit

GoldHaven’s Magno Project is situated within the Cassiar Terrane of northern British Columbia, the same regional geological setting that hosts Coeur Mining’s Silvertip silver-lead-zinc deposit, a well-established carbonate replacement deposit (CRD).

Magno exhibits several geological characteristics associated with the Silvertip model, including carbonate-hosted silver-lead-zinc mineralization, manto- and chimney-style replacement features, and multiple mineralized zones. These similarities provide an established exploration framework for evaluating the broader potential of Magno’s polymetallic system.

GoldHaven is integrating modern geophysical data, geological mapping and ongoing drilling to better understand the distribution and potential continuity of mineralization across its more than 37,000-hectare property.

The comparison is geological in nature only. Mineralization at Silvertip is not necessarily indicative of mineralization at Magno, and no mineral resource has been established at D Zone.

Figure 2: Magno project location bordering Coeur’s Silvertip Holdings and Cassiar Gold Corp.

Next Steps

GoldHaven’s near-term exploration activities include:

1. Continuing drilling across additional targets within the D Zone system.
2. Completing laboratory analysis and reporting assay results following QA/QC review.
3. Integrating geological, geochemical and geophysical datasets to evaluate the distribution and potential continuity of mineralization.

The Magno Project covers more than 37,000 hectares in the Cassiar District and hosts multiple exploration targets, including silver-lead-zinc mineralization at D Zone and Magno, together with tungsten-bearing skarn systems at Kuhn and Dead Goat.

Technical Notes

The historical 7.6-metre D Zone intersection has not been independently verified and is not necessarily indicative of current drill results. Previously reported sulphide intervals are cumulative visual downhole measurements from separate intervals, not true widths, and do not establish laboratory assay grades or economic mineralization. Grab samples are selective and are not representative of deposit-wide grades.

Qualified Person
The scientific and technical information in this news release has been reviewed and approved by Raymond Wladichuk, P.Geo., a non-independent Qualified Person under National Instrument 43-101, prior to dissemination.

About GoldHaven Resources Corp.

GoldHaven Resources Corp. is a Canadian junior exploration company focused on advancing highly prospective mineral projects in North and South America. The Company’s flagship asset is the district-scale Magno Project in the Cassiar District of northern British Columbia. GoldHaven also owns the Three Guardsmen copper-gold project in British Columbia and the Copeçal Gold Project in Mato Grosso, Brazil. In addition, the Company holds a portfolio of critical mineral projects in Brazil.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the inability of the Company to enter into definitive agreements in respect of possible Letters of Intent, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis and filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

• Drilling continuing across additional targets within the D Zone system, including evaluation of the geometry and potential continuity of the mineralized system
• The completion of laboratory analysis and the timing of reporting assay results following QA/QC review
• The Company’s plans to integrate geological, geochemical and geophysical datasets to evaluate the distribution and potential continuity of mineralization across the Magno Project
• The silver-lead-zinc potential of the D Zone system and the Company’s plans to further evaluate that potential as assay results are received
• The use of geological similarities with the Silvertip deposit as an exploration framework for evaluating the broader potential of Magno’s polymetallic system

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/92689088-8785-4d0d-996a-9af2f958d947

https://www.globenewswire.com/NewsRoom/AttachmentNg/8ac86514-1b47-4840-9675-777947fe8199

NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.

Fiscal 2026 and Recent Corporate Highlights

• NDA submitted for remibetadex (Trappsol® Cyclo™). On October 28, 2026, Cyclo Therapeutics submitted a New Drug Application (NDA) to the FDA seeking approval of remibetadex for the treatment of Niemann-Pick Disease Type C. The NDA is supported by the Phase 3 TransportNPC™ study, completed in June 2026, which did not meet its primary endpoint in the overall population (p=0.19) but showed 71% slowing of disease progression in a prespecified analysis of patients receiving background miglustat and/or leucine therapy (p=0.046), and by an overall survival analysis versus matched registry controls. The NDA includes a request for a rare pediatric disease priority review voucher.
• MIT license in Alzheimer’s disease. In April 2026, Cyclo entered into an exclusive, worldwide license with the Massachusetts Institute of Technology for the use of hydroxypropyl-β-cyclodextrin in Alzheimer’s disease.
• LipoMedix. In June 2026, an investigator-initiated Phase II trial of Promitil® with radiotherapy in patients with cisplatin-ineligible head and neck cancer was launched in Israel.
• Rafael Medical Devices. Continued the U.S. commercial build-out of the FDA-cleared VECTR™ System, including its regional distributor network.

Rafael Holdings, Inc. Fourth Quarter Fiscal Year 2026 Financial Results

As of July 31, 2026, we had cash and cash equivalents of $22.1 million.

For the three months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $9.2 million, or $0.18 per share, versus a net loss of $12.1 million, or $0.28 per share in the year ago period. The year over year decrease in net loss is largely attributable to a decrease in general and administrative expenses.

Research and development expenses were $7.5 million for each of the three months ended July 31, 2026 and 2025.

General and administrative expenses were $2.4 million for the three months ended July 31, 2026, compared to $5.5 million in the year ago period. The year over year decrease relates to a decrease in payroll, stock-based compensation expense and professional fees.

Rafael Holdings, Inc. Full Fiscal Year 2026 Financial Results

For the twelve months ended July 31, 2026, we recorded a net loss attributable to Rafael Holdings of $29.6 million, or $0.58 per share, versus a net loss of $30.5 million, or $1.04 per share in the year ago period. The year over year decrease in net loss reflects a $4.4 million gain on Cornerstone’s settlements of accounts payable and convertible notes payable and the absence of prior-year unrealized losses on our investment in Cyclo, partially offset by higher research and development expenses following the consolidation of Cyclo Therapeutics in March 2025.

Research and development expenses were $24.3 million for the twelve months ended July 31, 2026, compared to $12.8 million in the year ago period. The year over year increase was primarily attributable to a $13.4 million increase in Cyclo’s research and development expenses in fiscal 2026, as well as an increase in R&D stock-based compensation expense of $0.4 million, offset by decreases in R&D payroll of $1.5 million, and in clinical trial and other expenses of $0.8 million.

General and administrative expenses were $9.7 million for the twelve months ended July 31, 2026, compared to $13.8 million in the year ago period. The decrease of $4.1 million versus the prior year is primarily attributable to decreases in professional fees of $1.3 million, primarily due to merger-related costs in the prior year, stock-based compensation expense of $1.2 million, payroll expense of $0.6 million due to terminations, and other expenses.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex (Trappsol® Cyclo™), for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C (“NPC”) and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the FDA’s review of our NDA for remibetadex, including whether it will be accepted for filing, granted priority review or approved; our eligibility for and ability to monetize a priority review voucher; plans regarding the further evaluation of clinical data; and the potential of our pipeline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk that the FDA may not accept for filing or approve our NDA, including because the Phase 3 TransportNPC™ study did not meet its primary endpoint in the overall population, our need for additional financing and the substantial doubt about our ability to continue as a going concern, and those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2026, and our other filings with the SEC.  These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:
Barbara Ryan
barbara.ryan@rafaelholdings.com
(203) 274-2825

RAFAEL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
	July 31,
	2026				2025
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	22,074			$	52,769
Prepaid clinical costs		1,839				1,045
Other receivables		—				1,206
Accounts receivable, net of allowance for credit losses of $245 at July 31, 2026 and July 31, 2025		444				627
Inventory		377				281
Prepaid expenses and other current assets		1,083				786
Total current assets		25,817				56,714
Property and equipment, net		1,503				1,596
Non-current prepaid clinical costs		457				1,399
Convertible notes receivable classified as available-for-sale		2,044				1,858
Goodwill		19,939				19,939
Intangible assets, net		863				994
In-process research and development		31,575				31,575
Investments		750				—
Other assets		107				34
TOTAL ASSETS	$	83,055			$	114,109
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable	$	7,014			$	6,893
Accrued expenses		2,943				3,304
Convertible notes payable		608				614
Due to related parties, net		355				723
Other current liabilities		67				66
Total current liabilities		10,987				11,600
Accrued expenses, noncurrent		—				3,895
Convertible notes payable, noncurrent		2				78
Deferred income tax liability		43				138
Other liabilities		53				27
TOTAL LIABILITIES	$	11,085			$	15,738
COMMITMENTS AND CONTINGENCIES
EQUITY
Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2026 and July 31, 2025		8				8
Class B common stock, $0.01 par value; 200,000,000 shares authorized, 51,393,279 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2026, and 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025		514				508
Additional paid-in capital		323,438				322,161
Accumulated deficit		(261,898	)			(232,263	)
Treasury stock, at cost; 101,487 Class B shares as of July 31,  2026 and July 31,  2025		(168	)			(168	)
Accumulated other comprehensive income related to unrealized income on available-for-sale securities		544				358
Accumulated other comprehensive income related to foreign currency translation adjustment		3,871				3,787
Total equity attributable to Rafael Holdings, Inc.		66,309				94,391
Noncontrolling interests		5,661				3,980
TOTAL EQUITY		71,970				98,371
TOTAL LIABILITIES AND EQUITY	$	83,055			$	114,109

RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
	Three Months Ended July 31,								Year Ended July 31,
	2026				2025				2026				2025
	(unaudited)
Revenues	$	244			$	350			$	874			$	917
Cost of infusion technology revenue		—				—				—				106
Cost of product revenue		13				19				42				28
G&A expenses		2,444				5,497				9,704				13,781
R&D expenses		7,467				7,547				24,333				12,823
Depreciation and amortization		51				50				204				288
Loss on impairment of goodwill		–				–				–				3,050
Operating Loss		(9,731	)			(12,763	)			(33,409	)			(29,159	)
Interest income		213				467				1,236				1,996
Realized gain on available-for-sale securities		—				—				—				178
Unrealized (loss) gain on investment – Cyclo		—				—				—				(5,144	)
Unrealized (loss) gain on convertible notes receivable, due from Cyclo		—				—				—				(719	)
Interest expense		(6	)			(168	)			(333	)			(658	)
Gain on settlement of accounts payable and convertible notes payable		464				—				4,422				—
Other income		63				236				117				310
Loss before income taxes		(8,997	)			(12,228	)			(27,967	)			(33,196	)
Benefit from taxes		65				174				13				2,553
Consolidated net loss		(8,932	)			(12,054	)			(27,954	)			(30,643	)
Consolidated net loss		(8,932	)			(12,054	)			(27,954	)			(30,643	)
Net income (loss) attributable to noncontrolling interests		244				40				1,681				(123	)
Net loss attributable to Rafael Holdings, Inc.	$	(9,176	)		$	(12,094	)		$	(29,635	)		$	(30,520	)
Loss per share attributable to common stockholders
Basic and Diluted	$	(0.18	)		$	(0.28	)		$	(0.58	)		$	(1.04	)
Weighted average number of shares used in calculation of loss per share – basic and diluted		51,586,276				43,011,360				51,393,118				29,422,221